RANKL can activate the NF-κB pathway, and mice lacking the p50 and p52 NF-κB subunits develop osteopetrosis caused by the arrested generation of osteoclasts (11, 12 In vitro osteoclast formation assay ⎯ Murine osteoclasts were generated from bone marrow The antibody had the following cross-reactivity determined by comparing the bound/free ratios with several eicosanoids: PGE 2 , 100%; PGE 1 , 25%; PGF 2α , 0.04%; and 6-keto-PGF 1α , <0.1%. (Fig. 2, A and B) . formation in a dose-dependent manner (Fig. 3A) .
, inhibits singlet oxygen-induced DNA damage in human lymphoblast cells (19) , and protects human red blood cells during photodynamic treatment (20) . Moreover, Trolox selectively enhances arsenic-mediated apoptosis in several cancer cells, including myeloma and breast cancer cells (21) . Recently, Quintanilla et al. (22) showed that Trolox protects the neurotoxicity mediated by amyloid β-peptide and hydrogen peroxide through a mechanism that involves the modulation of the Wnt signaling pathway. In animal models, Trolox improves ischemia-induced hepatic drugmetabolizing dysfunction (23) and enhances the anti-lymphoma effects of arsenic trioxide (24) .
Despite its various beneficial effects, little is known about the effects of Trolox on osteoclastic bone loss. In the present study, we investigated the effects of Trolox and the molecular mechanisms of its action on osteoclast development in vitro and in vivo.
Here we show that Trolox inhibits osteoclast formation by suppressing RANKL induction and its critical downstream target gene, c-Fos.
EXPERIMENTAL PROCEDURES
Reagents and materials ⎯ Penicillin, streptomycin, α-MEM, and fetal bovine serum In vitro osteoclast formation assay ⎯ Murine osteoclasts were generated from bone marrow cells as previously described (25 Table 1 Table 1 ). In BMMs, the expression levels of the Hmox1 gene, which was previously shown to regulate osteoclast differentiation (44), decreased in response to RANKL, whereas
Trolox reversed the decrease (Supplemental Table 2 ). The suppressive effects of Trolox on the two genes were confirmed with real-time PCR analyses (Supplemental Fig. 3 ). However, without Trolox (500 μM) and RANKL (100 ng/ml) for 6 days. After culturing, the generated osteoclasts were detected by TRAP staining, and TRAP-positive multinucleated cells containing three or more nuclei were counted as osteoclasts (*, P < 0.01). B, Primary osteoblasts were pretreated with Trolox or vehicle (dimethylsulfoxide) for 24 h and were then stimulated with IL-1 (10 ng/ml) for 24 h.
After culturing, total RNA was isolated, and the expression of mRNA for RANKL and OPG was analyzed by real-time quantitative PCR with HPRT mRNA as an endogenous control. C, Osteoblasts were treated as in B. The amounts of RANKL (*, P < 0.01 versus untreated control; #, P < 0.01 versus group treated with IL-1 only) and OPG (*, P < 0.01 versus untreated control) were determined by using ELISA kits in cell lysates and in cell culture media, respectively.
FIGURE 2. Effects of Trolox on IL-1-induced PGE 2 synthesis in osteoblasts.
A, Primary osteoblasts were pretreated with Trolox (500 μM) or vehicle (dimethylsulfoxide) for 24 h and were then stimulated with IL-1 (10 ng/ml) for the indicated times. B, Osteoblasts pretreated with Trolox (100-500 μM) were stimulated with IL-1 (10 ng/ml) for 24 h. the PGE 2 concentration (*, P < 0.01 versus untreated control; #, P < 0.01 versus group treated with IL-1 only) in the culture medium was determined by EIA. C, Primary osteoblasts were treated with or without IL-1 (10 ng/ml), Trolox (500 μM), and PGE 2 (1 nM) for 24 h. Expression of mRNA for RANKL and OPG was analyzed by real-indicated days (*, P < 0.01 versus untreated control). D, BMMs were treated with (ii and iii) or without (i) Trolox at the beginning of the culture period, and Trolox was continued (ii) or withdrawn (iii) on day 2. E, The cocultured osteoclasts were replated on OAAS plates as described in EXPERIMENTAL PROCEDURES, incubated with or without Trolox (100 and 500 μM) for 1 h, and then further cultured in the presence of RANKL (100 ng/ml) for 24 h. Resorbed pits were photographed (left), and the pit areas were analyzed (right) after osteoclasts were removed. F, Purified mature osteoclasts from the coculture were incubated with Trolox (100 and 500 μM) for 1 h were then and further cultured in the presence of RANKL (100 ng/ml) for 24 h. After that, surviving osteoclasts were detected by TRAP staining (left), and the number of osteoclasts was counted (right). Affymetrix microarray data were obtained from osteoblats treated with vehicle, IL-1 (10ng/ml), or IL-1 plus Trolox (500 μM) for 24 h. cRNA samples were hybridized to an Affymetrix Mouse ST 1.0
Gene Chip. This table shows genes induced or reduced more than twofold by IL-1 plus Trolox compared to IL-1-treated group.
Supplemental Table 2 Functional Affymetrix microarray data were obtained from BMMs treated with vehicle, RANKL (100 ng/ml), or RANKL plus Trolox (500 μM) in the presence of M-CSF (30 ng/ml) for 24 h. cRNA samples were
